

Protect Pharmaceuticals Corp

A Wyoming Corporation

30 N Gould St. Suite R
Sheridan WY 82801

+30-6946084637
kkastanas@proton.me

Quarterly Report

For the period ending 3/31/2026 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

57,451,378 as of 3/31/2026 (Current Reporting Period Date or More Recent Date)

57,451,378 as of 12/31/2024 (Most Recent Completed Fiscal Year End)

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁵ of the company has occurred during this reporting period:

Yes: No:

⁵ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Previously Interstate Development Inc. until 01-2007.

Previously Pro-Tect, Inc. 1/2007 – 5/2010

Previously Protect Pharmaceuticals Corp. 2010-2018

An erroneous name change was filed the state of Nevada in 2018 but never implemented

Name restored to Protect Pharmaceuticals Corp.in 2020

Current State and Date of Incorporation or Registration: Wyoming

Standing in this jurisdiction: (e.g. active, default, inactive): Active (Good Standing)

Prior Incorporation Information for the issuer and any predecessors during the past five years:

N/A

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

N/A

List any company name change, stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

N/A

Address of the issuer's principal executive office:

30 N Gould St. Suite R
Sheridan WY 82801

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: ClearTrust LLC
Phone: (813) 235-4490
Email: inbox@cleartrusttransfer.com
Address: 16540 Pointe Village Dr Suite 210, Lutz, FL 33558

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>PRTT</u>	
Exact title and class of securities outstanding:	<u>COMMON STOCK</u>	
CUSIP:	<u>74364W203</u>	
Par or stated value:	<u>.005</u>	
Total shares authorized:	<u>100,000,000</u>	as of date: <u>3/31/2026</u>
Total shares outstanding:	<u>57,451,378</u>	as of date: <u>3/31/2026</u>
Total number of shareholders of record:	<u>300</u>	as of date: <u>3/31/2026</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of securities outstanding: Preferred Series "A"
CUSIP: NONE
Par or stated value: .001
Total shares authorized: 10,000,000 as of date: 3/31/2026
Total shares outstanding: 1,000,000 as of date: 3/31/2026
Total number of shareholders of record: 1 as of date: 3/31/2026

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

None

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Preferred Series A Shares vote 100 votes for each share. There are no conversion rights to common shares.

3. Describe any other material rights of common or preferred stockholders.

None

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance:</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date	Common:	Preferred:							
Date <u>12/31/2024</u>	Common: <u>57,451,378</u>	Preferred: <u>1,000,000</u>							
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____	_____	_____

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Company has been in the Logistics business and is currently transitioning to Textiles and Technologies.

- B. List any subsidiaries, parent company, or affiliated companies.

None

- C. Describe the issuers' principal products or services.

Textiles and Software as a Service. The company is currently not generating revenue.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company leases a small office for a physical address and programmers and directors and officers work abroad.

6) All Officers, Directors, and 5% Beneficial Owners of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, ≥ 5% beneficial owner)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Konstantinos Kastanas	CEO	Athens, Greece	0	NA	0
Anadolu Group (Boris Stepanov)	Beneficial Owner	Istanbul, Turkey	6,000,000	Common	10.4%
Steve Wang	Beneficial Owner	Tapei, Taiwan	1,000,000	Preferred Series A	100%

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Accountant or Auditor

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____

Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): _____
Discord: _____
LinkedIn _____
Facebook: _____
[Other] _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: **Konstantinos Kastanas**
Title: **CEO**
Relationship to Issuer: **Officer/Director**

B. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: **Michael Hess**
Title: **Accountant**
Relationship to Issuer: **Accountant**

Describe the qualifications of the person or persons who prepared the financial statements:⁷ **Mr. Hess has been working with public companies and preparing financial statements for over 15 years.**

Provide the following qualifying financial statements:

⁷ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity);
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable.” Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Konstantinos Kastanas certify that:

1. I have reviewed this Disclosure Statement for Protect Pharmaceuticals Corp;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

05/08/2026 [Date]

/s/ Konstantinos Kastanas [CEO's Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

Principal Financial Officer:

I, Konstantinos Kastanas certify that:

1. I have reviewed this Disclosure Statement for Protect Pharmaceuticals Corp;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

05/08/2026 [Date]

/s/ Konstantinos Kastanas [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

PROTECT PHARMACEUTICAL CORPORATION
UNAUDITED BALANCE SHEETS

	March 31, 2026	December 31, 2025
ASSETS		
CURRENT ASSETS		
Prepaid expenses	-	1,500
Total current assets	-	1,500
TOTAL ASSETS	-	1,500
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
Current liabilities:		
Notes payable, related party	4,500	4,500
Total current liabilities	4,500	4,500
TOTAL LIABILITIES	4,500	4,500
STOCKHOLDERS' EQUITY (DEFICIT)		
Preferred stock series A; \$0.001 par value, 10,000,000 and 10,000,000 shares authorized and 1,000,000 and 1,000,000 shares issued and outstanding	1,000	1,000
Common stock; \$0.005 par value, 100,000,000 and 100,000,000 shares authorized and 57,451,378 and 57,451,378 shares issued and outstanding	287,257	287,257
Additional paid-in capital	6,456,881	6,456,881
Retained earnings	(6,749,638)	(6,748,138)
Total stockholders' equity (deficit)	(4,500)	(3,000)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	\$ -	\$ 1,500

The accompanying notes are an integral part of these unaudited financial statements.

PROTECT PHARMACEUTICAL CORPORATION
UNAUDITED STATEMENTS OF OPERATIONS

	For the Three Months Ended	
	March 31,	
	2026	2025
OPERATING EXPENSES		
General and administrative	\$ 1,500	\$ -
Total operating expenses	1,500	-
Loss from Operation	(1,500)	-
Net loss from continuing operations	(1,500)	-
Net income from discontinued operations	-	6,563,000
Net income (loss)	\$ (1,500)	\$ 6,563,000
Basic net income (loss) per common share		
Continuing operations	\$ (0.00)	\$ -
Discontinued operations	\$ -	\$ 0.11
Net income (loss)	\$ (0.00)	\$ 0.11
Basic weighted average common shares outstanding	57,451,378	57,451,378

The accompanying notes are an integral part of these unaudited financial statements.

PROTECT PHARMACEUTICAL CORPORATION
UNAUDITED STATEMENTS OF CASH FLOWS

	For the Three Months Ended March 31,	
	2026	2025
Cash flows from operating activities:		
Net income (loss)	\$ (1,500)	\$ 6,563,000
Changes in operating assets and liabilities:		
Prepaid assets	1,500	-
Discontinued assets	-	1,366,000
Discontinued liabilities	-	(12,178,000)
Net cash used in operating activities	-	(4,249,000)
Cash flows from investing activities:		
Cash from discontinued investing activities	-	5,106,000
Net cash provided by financing activities	-	5,106,000
Net change in cash	-	857,000
Cash, beginning of period	-	18,216,000
Cash, end of period	\$ -	\$ 19,073,000

The accompanying notes are an integral part of these unaudited financial statements.

PROTECT PHARMACEUTICAL CORPORATION
UNAUDITED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

	Preferred Series A		Common Stock		Additional Paid-in Capital	Retained Earnings	Total Stockholders' Equity (Deficit)
	Shares	Amount	Shares	Amount			
Balance, December 31, 2025	1,000,000	\$ 1,000	57,451,378	\$ 287,257	\$ 6,456,881	\$ (6,748,138)	\$ (3,000)
Net loss for three months ended March 31, 2026	-	-	-	-	-	(1,500)	(1,500)
Balance, March 31, 2026	<u>1,000,000</u>	<u>\$ 1,000</u>	<u>57,451,378</u>	<u>\$ 287,257</u>	<u>\$ 6,456,881</u>	<u>\$ (6,749,638)</u>	<u>\$ (4,500)</u>

	Preferred Series A		Common Stock		Additional Paid-in Capital	Retained Earnings	Total Stockholders' Equity (Deficit)
	Shares	Amount	Shares	Amount			
Balance, December 31, 2024	1,000,000	\$ 1,000	57,451,378	\$ 287,257	\$ 6,456,881	\$ 325,943,862	\$ 332,689,000
Net income for the three months ended March 31, 2025	-	-	-	-	-	6,563,000	6,563,000
Balance, March 31, 2025	<u>1,000,000</u>	<u>\$ 1,000</u>	<u>57,451,378</u>	<u>\$ 287,257</u>	<u>\$ 6,456,881</u>	<u>\$ 332,506,862</u>	<u>\$ 339,252,000</u>

-

The accompanying notes are an integral part of these unaudited financial statements.

PROTECT PHARMACEUTICAL CORPORATION
NOTES TO UNAUDITED FINANCIAL STATEMENTS
MARCH 31, 2026 AND DECEMBER 31, 2025

NOTE 1 - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

The unaudited financial statements presented are those of Protect Pharmaceutical Corporation (“Protect”, or the “Company”). The Company was operating as a logistics company until July 1, 2025. On July 1, 2025, the owners of all of the preferred stock of Protect agreed to transfer all of its ownership positions in the Company to third party United States based investors in exchange for the foreign logistics operations, exiting the logistics business.

Basis of Presentation

The financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America. In the opinion of management, the accompanying unaudited interim financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the financial position and the results of operations for the interim period presented herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or for any future period. Notes to the financial statements which would substantially duplicate the disclosure contained in the financial statements for fiscal 2026 have been omitted.

Cash Equivalents

Protect considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.

Use of Estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Revenue Recognition Policy

Protect recognizes revenue in accordance with the provisions of Accounting Series Codification (“ASC”) 606, *Revenue From Contracts With Customers* (“ASC 606”), which provides guidance on the recognition, presentation, and disclosure of revenue in financial statements. ASC 606 outlines the basic criteria that must be met to recognize revenue and provides guidance on disclosure related to revenue recognition policies. In general, the Company recognizes revenue based on the allocation of the transaction price to each performance obligation as each performance obligation in a contract is satisfied.

Protect did not recognize any revenue during the three months ended March 31, 2026 and 2025.

Stock-Based Compensation

Protect records stock-based compensation using the fair value method. Equity instruments issued to employees and the cost of the services received as consideration are accounted for in accordance with ASC 718, *Stock Compensation* and are measured and recognized based on the fair value of the equity instruments issued. All transactions with non-employees in which goods or services are the consideration received for the issuance of equity instruments are accounted for in accordance with ASC 515, *Equity-Based Payments to Non-Employees*, based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. There were no outstanding stock-based compensation plans or awards issued as of March 31, 2026 and December 31, 2025.

Fair Value of Financial Instruments

ASC 820, *Fair Value Measurements* (“ASC 820”) and ASC 825, *Financial Instruments* (“ASC 825”), requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 - Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 - Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 - Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The carrying values of cash, other current assets, property, accounts payable and accrued expenses approximate fair value. Pursuant to ASC 820 and 825, the fair value of cash is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets.

New Accounting Pronouncements

Protect has implemented all new accounting pronouncements that are in effect and that may impact its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Basic and Diluted Loss Per Share

Protect presents basic earnings per share (EPS) on the face of the statements of operation. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period including convertible debt, stock options, and warrants, using the treasury stock method, and convertible debt instrument, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.

The calculation of basic and diluted net loss per share is as follows:

	For the Three Months Ended March 31,	
	2026	2025
Basic and Diluted Loss Per Share:		
Numerator:		
Net loss from continuing operations	\$ (1,500)	\$ -
Net income from discontinued operations	-	6,563,000
Net income (loss)	<u>\$ (1,500)</u>	<u>\$ 6,563,000</u>
Denominator:		
Weighted average common shares outstanding, basic and diluted	<u>57,451,378</u>	<u>57,451,378</u>
Basic and diluted net loss per share from continuing operations	<u>\$ (0.00)</u>	<u>\$ -</u>
Basic and diluted net income per share from discontinued operations	<u>\$ -</u>	<u>\$ 0.11</u>
Basic and diluted net income (loss) per share	<u>\$ (0.00)</u>	<u>\$ 0.11</u>

Income Taxes

Protect records income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized based on the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and attributable to operating loss and tax credit carryforwards. Accounting standards regarding income taxes requires a reduction of the carrying amounts of deferred tax assets by a valuation allowance, if based on the available evidence, it is more likely than not that such assets will not be realized. Accordingly, the need to establish valuation allowances for deferred tax assets is assessed at each reporting period based on a “more likely than not” realization threshold. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carryforward periods, the Company’s experience with operating loss and tax credit carryforwards not expiring unused, and tax planning alternatives.

Significant judgment is required in evaluating the Company’s tax positions and determining its provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. Accounting standards regarding uncertainty in income taxes provides a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely, based solely on the technical merits, of being sustained on examinations. Protect considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes.

NOTE 2 – LOANS PAYABLE

As of March 31, 2026, the Company owes \$4,500 for cash loans from an individual. The loan is unsecured, does not bare interest and is due on demand. The balance of the loans was \$4,500 and \$4,500 as of March 31, 2026 and December 31, 2025, respectively.

NOTE 3 – DISCONTINUED OPERATIONS

During July 2025, Protect’s owners agreed to give all of its ownership in the Company to an individual in exchange for the operating assets and liabilities of the Company’s logistics business. Effectively, the transaction reverts the historical foreign operations of the Company to the prior owners, leaving Protect with no operating assets or liabilities as of March 31, 2026.

The operating results of the Company’s discontinued operations for the three months ended March 31, 2025 are as follows:

	For the Three Months Ended March 31, 2025
Revenues	<u>\$ 25,662,000</u>
Cost of Sales	<u>(11,270,000)</u>
Gross Profit	14,392,000
Operating Expenses:	
Selling and marketing	1,608,000
Research and development	604,000
General and administrative	<u>3,429,000</u>
Total operating expenses	5,641,000
Operating Income Before Taxes	<u>8,751,000</u>
Tax expense	<u>(2,188,000)</u>
Income from discontinued operations	<u><u>\$ 6,563,000</u></u>

NOTE 4 - GOING CONCERN

Protect's financial statements are prepared using Generally Accepted Accounting Principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, Protect has recently accumulated losses since its inception and has had negative cash flows from operations, which raise substantial doubt about its ability to continue as a going concern. Management's plans with respect to alleviating the adverse financial conditions that caused management to express substantial doubt about Protect 's ability to continue as a going concern are as follows:

The ability to continue Protect's operations depends on its ability to generate and grow revenue and results of operations as well as its ability to access capital markets when necessary to accomplish strategic objectives. The Company expects to continue to incur losses for the immediate future and will need additional equity or debt financing until it can achieve profitability and positive cash flows from operating activities. Future capital requirements for operations will depend on many factors, including the ability to generate revenues and obtain capital.

There can be no assurance that Protect will be able to achieve its business plans, raise any more required capital or secure the financing necessary to achieve its current operating plan. The ability of Protect to continue as a going concern is dependent upon its ability to successfully accomplish the plan described in the preceding paragraph and eventually attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.